7 May 2024
IXICO plc
("IXICO" or the "Company")
Notice of half-year results and investor presentation via Investor Meet Company.
IXICO PLC is pleased to announce that it will release its half-year results on Tuesday 21 May 2024.
Giulio Cerroni and Grant Nash will provide a live presentation relating to these results and a broader Company update via Investor Meet Company on 21 May 2024, 16:30 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 20 May 2024, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | ||
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| ||
| |
| ||
| Cavendish Capital Markets Limited (Nominated adviser and sole broker) | +44 (0) 20 7220 0500 | ||
| Giles Balleny / Dan Hodkinson (Corporate Finance) | |
| |
| Nigel Birks/Harriet Ward (Corporate Broking) | |
| |
| Michael F Johnson / Tamar Cranford Smith (Sales) | |
| |
| |
|
| |
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
